/ Print /

Business Strategy

Four ways health execs can prep for costly CAR-T cell therapiesWith the high efficacy and dire diagnosis, there will be demand for both Kymriah and Yescarta. Here’s how to manage the monetary impact.
Payers can predict budget implications of high-cost drugs in the pipelineA University of Massachusetts clinical consulting pharmacist shows how assessing budget implications can be accomplished.
Payers need access to pre-approval drug informationPre-drug-approval forecasting and budgeting is increasingly important for payers. Is a safe harbor for manufacturers necessary?
Five ways to increase physician engagementOne expert says incentive programs to motivate physicians miss the mark. Here’s what he recommends instead.
Program uses provider, patient incentives to fight opioid epidemicProviders are coming up short when it comes to HEDIS measures related to substance abuse. Here’s how one health plan is changing that.
Medicare Advantage vs. specialized Medicare Advantage plans: Outcome effectsAvalere Health analysis has intriguing results about beneficiaries enrolled in diabetes-focused chronic condition special needs plans.
Trump’s steps to undo the ACA: Top takeaways from healthcare insidersTrump takes two steps to dissolve the ACA. Find out what the experts think about these two important actions.
Five ways Trump’s efforts to strip the ACA will affect healthcareHere’s a quick guide to the meaning behind Trump’s executive order and decision to stop cost-sharing reduction payments.
Five key focus areas for building a consumer-centric healthcare organizationHere’s how to take consumer-centricity more seriously as expectations increase.
Opinion: Four reasons Texas Health Aetna joint venture is workingAs the industry moves to a value-based care model, here’s how one North Texas partnership is reinventing healthcare.